Suppr超能文献

体外细胞因子血液吸附在左心室辅助装置植入治疗心原性休克患者中的初步经验。

Preliminary Experience of Extracorporeal Cytokine Hemoadsorption during Left Ventricular Assist Device Implantation in Cardiogenic Shock Patients.

机构信息

Univeristy Heart and Vascular Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Department of Anesthesiology, Center of Anesthesiology and Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

出版信息

Thorac Cardiovasc Surg. 2024 Jun;72(4):266-272. doi: 10.1055/s-0042-1757300. Epub 2022 Oct 10.

Abstract

BACKGROUND

Systemic inflammation due to cardiogenic shock is associated with vasoplegia leading to organ hypoperfusion, right heart failure, and poor clinical outcome. Extracorporeal cytokine hemoadsorption emerged to attenuate excessive levels of inflammatory cytokines, potentially improving patient outcomes. Nevertheless, its prognostic impact during high-risk left ventricular assist device (LVAD) implantation remains unknown.

METHODS

In total, 40 consecutive patients with advanced heart failure underwent continuous-flow LVAD implantation at our institution between 2018 and 2020. Out of 25 high-risk patients in cardiogenic shock (Interagency Registry for Mechanically Assisted Circulatory Support profile 1 and 2), 9 patients () underwent LVAD implantation with and 16 patients () without simultaneous cytokine hemoadsorption during cardiopulmonary bypass. Besides preoperative patient characteristics, postoperative lactate clearance, vasopressor administration and mean arterial pressure, perioperative complication, and 30-day mortality rates were retrospectively analyzed.

RESULTS

Apart from an increased rate of reoperations within the CytoSorb group, baseline characteristics including the severity of ventricular dysfunction and consecutive signs of end-organ failure were similar in both groups. Preoperative short-term mechanical circulatory support bridging was comparable (66.7 vs. 75%;  = 0.66) prior to LVAD implantation. Procedural characteristics including intraoperative volume management and postoperative vasopressor administration were similar in both groups. There was no difference regarding postoperative lactate clearance, although postoperative mean arterial pressure was significantly higher in the control group (71.3 vs. 57.4 mm Hg;  < 0.01). Furthermore, the 30-day mortality rate was significantly higher in the CytoSorb group (33.3 vs. 0.0%;  = 0.01).

CONCLUSION

Extracorporeal cytokine hemoadsorption during high-risk LVAD implantation was not associated with a decrease of postoperative vasopressor support, improved hemodynamics, or an accelerated lactate clearance.

摘要

背景

心源性休克引起的全身炎症与血管麻痹有关,导致器官灌注不足、右心衰竭和临床预后不良。细胞因子体外血液吸附技术的出现可以减轻过度的炎症细胞因子水平,从而有可能改善患者的预后。然而,在高危左心室辅助装置(LVAD)植入期间,其预后影响仍不清楚。

方法

在我院,2018 年至 2020 年间,连续有 40 例晚期心力衰竭患者接受了连续流动的 LVAD 植入。在 25 例心源性休克高危患者(机构间机械辅助循环支持注册 1 型和 2 型)中,9 例()在体外循环期间接受了 LVAD 植入和细胞因子血液吸附治疗,而 16 例()未接受同期细胞因子血液吸附治疗。除了术前患者特征外,还回顾性分析了术后乳酸清除率、血管加压素的应用和平均动脉压、围手术期并发症和 30 天死亡率。

结果

除 CytoSorb 组的再手术率增加外,两组的基线特征包括心室功能障碍的严重程度和随后的终末器官衰竭迹象均相似。LVAD 植入前短期机械循环支持桥接相似(66.7%比 75%;=0.66)。两组的手术特征包括术中容量管理和术后血管加压素的应用均相似。两组术后乳酸清除率无差异,尽管对照组术后平均动脉压明显较高(71.3 比 57.4mmHg;<0.01)。此外,CytoSorb 组的 30 天死亡率明显较高(33.3%比 0.0%;=0.01)。

结论

高危 LVAD 植入期间进行细胞因子体外血液吸附治疗并不能降低术后血管加压素的支持,改善血液动力学,或加速乳酸清除。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验